Funder
National Cancer Institute
Merck Sharp and Dohme United Kingdom
National Institutes of Health
National Heart, Lung, and Blood Institute
Subject
Cancer Research,Oncology,Hematology
Reference23 articles.
1. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma;Nowakowski;J Clin Oncol Off J Am Soc Clin Oncol,2021
2. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma;Younes;J Clin Oncol Off J Am Soc Clin Oncol,2019
3. Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL;Offner;Blood,2015
4. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the Phase III intergroup trial alliance/CALGB 50303;Bartlett;J Clin Oncol Off J Am Soc Clin Oncol,2019
5. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma;Tilly;N Engl J Med,2022